Ionis reports positive 12-month olezarsen data showing liver fat normalizing

Filed June 11, 2026 · Period ending June 12, 2026 · ~1 min read

Key Changes

• high

  Liver fat levels returned toward baseline after 24 months of treatment with 80mg dose, addressing a key safety concern about long-term fat accumulation in the liver.

  Item 7.01 view on EDGAR →
• medium

  Over 90% of eligible patients from original trials continued into extension study and remained enrolled, suggesting strong tolerability and physician confidence in the drug.

  Item 7.01 view on EDGAR →
• medium

  Olezarsen maintained favorable safety profile with longer-term treatment in patients with severe hypertriglyceridemia, supporting viability for chronic use.

  Item 7.01 view on EDGAR →